Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Pulmonology

Background:

• Small cell lung cancer (SCLC) presents significant challenges due to its aggressive nature, metastasis, recurrence, and resistance to conventional treatments.
• The long-standing platinum-etoposide chemotherapy regimen has limited efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the advancements in the application of immune checkpoint inhibitors (ICIs) for SCLC treatment.
• To explore the potential of ICIs as both monotherapy and in combination with other treatments like radiotherapy and targeted drugs.

Main Methods:

• Literature review of current research on immune checkpoint inhibitors in SCLC.
• Analysis of studies evaluating ICIs alone and in combination regimens.

Main Results:

• Immune checkpoint inhibitors (ICIs) have emerged as a promising monotherapy for SCLC, demonstrating significant therapeutic effects.
• Combination strategies involving ICIs with radiotherapy or molecular targeted drugs are being investigated for synergistic benefits and reduced toxicity.

Conclusions:

• Immune checkpoint inhibitors (ICIs) represent a paradigm shift in SCLC treatment, moving beyond traditional chemotherapy.
• Further research into optimizing ICI monotherapy and combination approaches is crucial to overcome current limitations and improve patient prognosis.